Hunter Perkins Capital Management LLC Has $375,000 Stock Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Hunter Perkins Capital Management LLC increased its position in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 3.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 64,040 shares of the company’s stock after acquiring an additional 2,025 shares during the period. Hunter Perkins Capital Management LLC owned about 0.12% of Voyager Therapeutics worth $375,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in VYGR. Allspring Global Investments Holdings LLC boosted its position in Voyager Therapeutics by 2.1% in the first quarter. Allspring Global Investments Holdings LLC now owns 99,306 shares of the company’s stock valued at $925,000 after buying an additional 2,030 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Voyager Therapeutics by 104.3% in the first quarter. China Universal Asset Management Co. Ltd. now owns 10,404 shares of the company’s stock valued at $97,000 after buying an additional 5,311 shares in the last quarter. Commonwealth Equity Services LLC acquired a new stake in Voyager Therapeutics in the first quarter valued at approximately $530,000. BNP Paribas Financial Markets boosted its position in Voyager Therapeutics by 198.6% in the first quarter. BNP Paribas Financial Markets now owns 48,769 shares of the company’s stock valued at $454,000 after buying an additional 32,437 shares in the last quarter. Finally, Empowered Funds LLC boosted its position in Voyager Therapeutics by 8.2% in the first quarter. Empowered Funds LLC now owns 39,471 shares of the company’s stock valued at $367,000 after buying an additional 2,975 shares in the last quarter. Institutional investors and hedge funds own 48.03% of the company’s stock.

Voyager Therapeutics Trading Up 17.7 %

VYGR traded up $1.21 during trading hours on Wednesday, hitting $8.06. The company’s stock had a trading volume of 725,719 shares, compared to its average volume of 637,331. The business’s 50-day moving average price is $6.51 and its 200-day moving average price is $7.75. Voyager Therapeutics, Inc. has a 12 month low of $5.71 and a 12 month high of $11.72. The stock has a market cap of $439.51 million, a price-to-earnings ratio of 27.04 and a beta of 0.91.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Tuesday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.20. The firm had revenue of $29.58 million during the quarter, compared to analyst estimates of $11.52 million. Voyager Therapeutics had a net margin of 6.28% and a return on equity of 3.31%. During the same period in the previous year, the firm earned ($0.51) earnings per share. On average, analysts forecast that Voyager Therapeutics, Inc. will post -1.44 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on VYGR. Leerink Partners began coverage on shares of Voyager Therapeutics in a report on Wednesday. They set an “outperform” rating and a $15.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Voyager Therapeutics in a research note on Tuesday, August 20th. Wedbush reduced their price objective on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. Finally, StockNews.com upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, October 11th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Voyager Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $17.43.

Insider Activity

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total transaction of $34,914.18. Following the transaction, the insider now owns 86,001 shares in the company, valued at $500,525.82. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 4.53% of the company’s stock.

Voyager Therapeutics Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.